India, June 25 -- Shares of Plus Therapeutics, Inc. (PSTV) were gaining around 120% in the pre-market activity on the Nadsaq after the company announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug or IND application for REYOBIQTM (Rhenium Re186 Obisbemeda) to treat pediatric brain cancers.
The trial will be referred to as the ReSPECT-PBC trial and is funded by a $3.0M research grant from the U.S. Department of Defense.
The clinical-stage pharmaceutical company focused on central nervous system or CNS cancers noted that the approval was for the treatment of pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma or HGG and ependymoma.
Pediatric HGG including ep...